AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01238692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL).
Study NCT03246633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perceptual Training
Description: Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
Study NCT01818297 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PrimeAdvanced® neurostimulator system
Description: Neurostimulator and associated components
Study NCT01818297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrimeAdvanced® neurostimulator system
Description: Neurostimulator and associated components
Study NCT03044860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE) with biopsy retrieval
Description: With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine
Study NCT02314507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua sha
Description: A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
Study NCT02314507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
Study NCT00890838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven-IV FO
Description: will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
Study NCT00217165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taurine
Description: taurine 2mg BID po
Study NCT00217165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taurine
Description: taurine 2mg BID po
Study NCT01950832 — intervention group
Intervention type: OTHER
Intervention: Investigating clinically normal patients with optic coherence tomography
Study NCT02035826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Economics Intervention
Description: Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
Study NCT00832897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.
Study NCT00832897 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.
Study NCT01014403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Enoxaparin 30 mg sq q 12 hours
Study NCT01014403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle
Study NCT04758494 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population.
Study NCT01896960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 15 micrograms of fentanyl
Description: Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
Study NCT00481065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1
Study NCT00481065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT00481065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a
Study NCT04167475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Description: Each probiotic capsule contains 1 x 10\^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
Study NCT04167475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
Study NCT03693248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant chemotherapy
Description: Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
Study NCT02137967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NaOCl pulpotomy
Description: Use 2.5% NaOCl as pulpotomy medicament for primary molars
Study NCT02137967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FC pulpotomy
Description: Use 20% Formocresol as pulpotomy medicament for primary molars
Study NCT02137967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Study NCT02137967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Formocresol
Study NCT04251364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Daily acetazolamide pill intake
Study NCT04251364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Daily atorvastatin pill intake
Study NCT04251364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily placebo pill intake
Study NCT03604185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choir Singing
Description: A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
Study NCT03604185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Appreciation
Description: A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
Study NCT04360967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Formula
Description: Standard Formula
Study NCT04360967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched Formula
Description: Nutrient-enriched Formula
Study NCT01493180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 ophthalmic suspension
Description: OPC-12759 ophthalmic suspension 2%
Study NCT01493180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate ophthalmic solution
Description: Sodium hyaluronate ophthalmic solution 0.1%
Study NCT01401504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3026
Description: oral
Study NCT02629731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom orthoses with varying degrees of hindfoot posting
Description: The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
Study NCT02359981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: An Android Smartphone with operating system version higher than 2.2
Study NCT02359981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: An Android Smartphone with operating system version higher than 2.2
Study NCT01410630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FLT-PET/CT
Description: Standard of Care
Study NCT01410630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET/CT
Description: Standard of Care
Study NCT01410630 — intervention group
Intervention type: DRUG
Intervention: FLT
Description: 5 mCi IV
Study NCT02506933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01151722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bevacizumab injection
Description: bevacizumab injection before vitrectomy
Study NCT01151722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bevacizumab injection
Description: bevacizumab injection after vitrectomy
Study NCT01795547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and aripiprazole once-monthly
Description: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
Study NCT01795547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone and paliperidone palmitate
Description: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
Study NCT03924401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Study NCT02004002 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance with normal protein intake
Description: Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
Study NCT02004002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintenance with protein restriction
Description: Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
Study NCT01428466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2585823
Description: CLDM1%/BPO3%
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01428466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide 3%
Description: Benzoyl peroxide 3%
Study NCT01428466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide 5%
Description: Benzoyl peroxide 5%
Study NCT01428466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: placebo
Study NCT03056105 — intervention group
Intervention type: OTHER
Intervention: Residential Insight Meditation Retreat
Description: Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet.
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04276324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Ten weeks of resistance training
Study NCT04276324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing sessions
Description: Testing sessions
Study NCT04276324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing sessions
Description: Testing sessions
Study NCT01783067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pearl millet
Description: Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
Study NCT01783067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified pearl millet
Description: Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
Study NCT04228848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
Study NCT04228848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
Study NCT00862095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every month for 3 months
Study NCT00862095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: target does 80 mg per day for 3 months
Study NCT00862095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Target does of 50 mg per day for 3 months
Study NCT01293071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic rotation
Description: Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
Study NCT01697280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine promotion messages
Description: The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings.
Study NCT01697280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccination Verification.
Description: EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
Study NCT00862095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Target dose 100 mg a day for 3 months
Study NCT00796588 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: remote preconditioning
Description: Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
Study NCT00796588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: remote preconditioning
Description: Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3462817 - IV
Description: Administered IV
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3462817 - SC
Description: Administered SC
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally.
Study NCT04152382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02652039 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires
Study NCT01370460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical tranexamic acid (2g/100mL 0.9% saline)
Study NCT01370460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL 0.9% sterile saline
Study NCT01438008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% sucrose po solution
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure.
Study NCT01438008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo po
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: Baseline Participant Assessment
Description: * Section 1 contains demographic questions~* Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~* Section 3 has the participant list all medication~* Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~* Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~* Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling
Study NCT01697280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution of Plastic Pouches to retain vaccination card
Description: At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.